MCID: SML001
MIFTS: 58

Small Cell Carcinoma

Categories: Rare diseases, Skin diseases, Genetic diseases, Cancer diseases, Respiratory diseases

Aliases & Classifications for Small Cell Carcinoma

MalaCards integrated aliases for Small Cell Carcinoma:

Name: Small Cell Carcinoma 12 14
Small Cell Carcinoma, Intermediate Cell 12 69
Small Cell Carcinoma - Intermediate Cell 12
Intermediate Cell Small Cell Carcinoma 12
Small Cell Carcinoma of Lung 69
Carcinoma, Small Cell 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0050685
NCIt 46 C4099
SNOMED-CT 64 189557009 5958006
UMLS 69 C0334239

Summaries for Small Cell Carcinoma

Disease Ontology : 12 A carcinoma that is an undifferentiated neoplasm composed of primitive-appearing cells.

MalaCards based summary : Small Cell Carcinoma, also known as small cell carcinoma, intermediate cell, is related to lung combined type small cell carcinoma and ureter small cell carcinoma. An important gene associated with Small Cell Carcinoma is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Endometrial cancer and Gastric cancer. The drugs Cisplatin and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and prostate, and related phenotypes are Decreased viability in esophageal squamous lineage and cellular

Related Diseases for Small Cell Carcinoma

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 4
Basal Cell Carcinoma 5 Basal Cell Carcinoma 6
Basal Cell Carcinoma 7 Cell Type Cancer
Cell Type Benign Neoplasm Basal Cell Carcinoma
Large Cell Carcinoma Basal Cell Carcinoma, Multiple

Diseases related to Small Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 434)
# Related Disease Score Top Affiliating Genes
1 lung combined type small cell carcinoma 34.3 NCAM1 SYP
2 ureter small cell carcinoma 34.3 CHGA SYP
3 gallbladder small cell carcinoma 33.7 CHGA ENO2 NCAM1 SYP
4 prostate small cell carcinoma 33.5 ASCL1 ENO2 KLK3
5 gastric small cell carcinoma 33.4 CHGA ENO2 NCAM1 PTPRC SYP
6 cervix small cell carcinoma 33.4 CHGA ENO2 NCAM1 SYP TP53
7 small cell carcinoma of the bladder 33.3 CHGA ENO2 KRT20 KRT7 NKX2-1 SYP
8 endometrial small cell carcinoma 32.6 ENO2 KIT NCAM1 PDGFRA PTPRC SYP
9 merkel cell carcinoma 30.6 CHGA ENO2 KIT KRT20 KRT7 NCAM1
10 pulmonary large cell neuroendocrine carcinoma 30.4 CHGA ENO2 SYP
11 small cell cancer of the lung 30.3 ASCL1 CALCA CHGA EGFR ENO2 KIT
12 ovarian mucinous neoplasm 30.0 ENO2 KRT20 KRT7 SYP
13 spindle cell carcinoma 29.9 ENO2 KRT7 SYP
14 prostate cancer 29.9 CHGA EGFR ENO2 KLK3 PTEN TMPRSS2
15 blastoma 29.9 NKX2-1 SYP TP53
16 mucinous cystadenocarcinoma 29.8 KRT20 KRT7 PTPRC
17 endocervical adenocarcinoma 29.8 KRT20 KRT7 TP53
18 follicular adenoma 29.7 CALCA NKX2-1 PTEN
19 bladder urothelial carcinoma 29.7 KRT20 KRT7 TP53
20 cystadenocarcinoma 29.6 KRT7 PTPRC TP53
21 li-fraumeni syndrome 29.6 EGFR PTEN TP53
22 basaloid squamous cell carcinoma 29.5 EGFR ENO2 KRT7 SYP TP53
23 meningioma, familial 29.5 NCAM1 PTEN SYP TP53
24 cystic teratoma 29.5 ENO2 KRT20 KRT7 NKX2-1 SYP TP53
25 astrocytoma 29.4 EGFR PTEN SYP TP53
26 suppression of tumorigenicity 12 29.4 CHGA KLK3 PTEN TMPRSS2
27 transitional cell carcinoma 29.4 EGFR ENO2 KRT20 KRT7 TP53
28 cervical adenocarcinoma 29.4 EGFR KRT20 KRT7 TP53
29 pulmonary blastoma 29.2 CHGA EGFR NKX2-1 SYP TP53
30 teratoma 29.2 ENO2 KIT KRT20 KRT7 NKX2-1 SYP
31 glioblastoma 29.1 EGFR PDGFRA PTEN TP53
32 pleomorphic carcinoma 29.0 EGFR KIT KRT7 NKX2-1 TP53
33 chordoma 29.0 EGFR KRT7 NCAM1 PDGFRA
34 adenosquamous carcinoma 28.9 EGFR KRT7 PDGFRA TP53
35 renal cell carcinoma, nonpapillary 28.9 EGFR ENO2 KIT KRT20 KRT7 NKX2-1
36 glioblastoma multiforme 28.9 EGFR PDGFRA PTEN TP53
37 large cell carcinoma 28.6 CHGA EGFR ENO2 KRT7 NCAM1 NKX2-1
38 large cell neuroendocrine carcinoma 28.4 ASCL1 CHGA EGFR ENO2 KIT KRT20
39 neuroendocrine tumor 27.8 ASCL1 CALCA CHGA ENO2 KRT20 KRT7
40 lung cancer 27.3 ASCL1 CHGA EGFR ENO2 KIT KRT20
41 ovarian small cell carcinoma 12.5
42 laryngeal small cell carcinoma 12.2
43 thymus small cell carcinoma 12.2
44 hypercalcemic type ovarian small cell carcinoma 12.2
45 colon small cell carcinoma 12.2
46 lung occult small cell carcinoma 12.1
47 bartholin's gland small cell carcinoma 12.1
48 ampulla of vater small cell carcinoma 12.0
49 pulmonary type ovarian small cell carcinoma 12.0
50 esophagus small cell carcinoma 12.0

Graphical network of the top 20 diseases related to Small Cell Carcinoma:



Diseases related to Small Cell Carcinoma

Symptoms & Phenotypes for Small Cell Carcinoma

GenomeRNAi Phenotypes related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.36 ASCL1 CHGA KIT KLK3 KRT7 NKX2-1

MGI Mouse Phenotypes related to Small Cell Carcinoma:

43 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.3 ENO2 ASCL1 KIT KRT7 NCAM1 EGFR
2 growth/size/body region MP:0005378 10.23 ENO2 ASCL1 CHGA KIT EGFR NKX2-1
3 endocrine/exocrine gland MP:0005379 10.22 ASCL1 KIT CHGA EGFR NKX2-1 PTPRC
4 mortality/aging MP:0010768 10.21 ASCL1 CHGA KIT NCAM1 EGFR NKX2-1
5 nervous system MP:0003631 10.15 ENO2 ASCL1 KIT NCAM1 EGFR NKX2-1
6 digestive/alimentary MP:0005381 10.1 KIT EGFR NKX2-1 PTPRC PDGFRA SMARCA4
7 neoplasm MP:0002006 10.06 KIT EGFR NKX2-1 PTPRC PDGFRA SMARCA4
8 craniofacial MP:0005382 10.05 ENO2 ASCL1 KIT EGFR PDGFRA SMARCA4
9 normal MP:0002873 10 ASCL1 KIT EGFR NKX2-1 PTPRC PDGFRA
10 no phenotypic analysis MP:0003012 9.92 ASCL1 CHGA KIT EGFR NKX2-1 PTPRC
11 pigmentation MP:0001186 9.63 ASCL1 KIT EGFR PDGFRA PTEN TP53
12 renal/urinary system MP:0005367 9.61 KIT CHGA KRT7 EGFR PTPRC PDGFRA
13 respiratory system MP:0005388 9.36 ASCL1 KIT EGFR NKX2-1 ENO2 PTPRC

Drugs & Therapeutics for Small Cell Carcinoma

Drugs for Small Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 411)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
2
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
3
Irinotecan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 97682-44-5, 100286-90-6 60838
4
Bupropion Approved Phase 4,Phase 3,Phase 2 34911-55-2, 34841-39-9 444
5
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
6
Nicotine Approved Phase 4,Phase 3,Phase 1 54-11-5 89594 942
7
Gefitinib Approved, Investigational Phase 4,Phase 2 184475-35-2 123631
8
Camptothecin Experimental Phase 4,Phase 3,Phase 2,Phase 1 7689-03-4
9 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
10 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
11 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1
12 topoisomerase I inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Antidepressive Agents Phase 4,Phase 3,Phase 1,Phase 2
15 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 2
16 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 3,Phase 2
17 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
18 Dopamine Agents Phase 4,Phase 3,Phase 2
19 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2
20 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
22 Psychotropic Drugs Phase 4,Phase 3,Phase 1,Phase 2
23 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Central Nervous System Stimulants Phase 4,Phase 3,Phase 1
25 Cholinergic Agents Phase 4,Phase 3,Phase 1
26 Nicotinic Agonists Phase 4,Phase 3,Phase 1
27 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
29
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
30
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
31
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
32
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
33
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
34
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
35
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
36
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
37
Dalteparin Approved Phase 3 9005-49-6
38
Heparin Approved, Investigational Phase 3,Phase 2 9005-49-6 46507594 772
39
Zoledronic acid Approved Phase 3,Phase 2 118072-93-8 68740
40
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 119413-54-6, 123948-87-8 60700
41
Mesna Approved, Investigational Phase 3 3375-50-6 598
42
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
43
Dacarbazine Approved, Investigational Phase 2, Phase 3,Phase 1 4342-03-4 5351166
44
Temozolomide Approved, Investigational Phase 2, Phase 3,Phase 1 85622-93-1 5394
45
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 241903 13342
46
Vinorelbine Approved, Investigational Phase 3,Phase 1,Phase 2 71486-22-1 44424639 60780
47
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1 216974-75-3
48 Amrubicin Approved, Investigational Phase 3,Phase 2,Phase 1 110267-81-7
49
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
50
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556

Interventional clinical trials:

(show top 50) (show all 782)

# Name Status NCT ID Phase Drugs
1 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
2 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
3 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer Recruiting NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
4 the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer) Not yet recruiting NCT03264794 Phase 4 Gefitinib Tab (CTTQ),First medication;Gefitinib Tab (CTTQ),From the 8th day of trial;Gefitinib tablets (Yi Ruisha),First medication;Gefitinib Tab 250 MG(CTTQ),From the 8th day of trial.
5 Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy Suspended NCT01720901 Phase 4 Icotinib
6 STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study Unknown status NCT00526396 Phase 3 cisplatin;etoposide;cisplatin;etoposide
7 Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient Unknown status NCT00826644 Phase 3 Belotecan/Cisplatin;Etoposide/Cisplatin
8 Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer Unknown status NCT00003606 Phase 3 cisplatin;cyclophosphamide;epirubicin hydrochloride;etoposide
9 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer Unknown status NCT00002858 Phase 3 cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide
10 Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer Unknown status NCT00003696 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;paclitaxel
11 Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer Unknown status NCT00011921 Phase 3 carboplatin;epirubicin hydrochloride;etoposide;etoposide phosphate;ifosfamide;paclitaxel
12 Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study) Unknown status NCT01555710 Phase 3 Carboplatin;Palifosfamide-tris;Etoposide;Carboplatin
13 Study of Picoplatin Efficacy After Relapse Unknown status NCT00465491 Phase 3 picoplatin
14 A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage Unknown status NCT00168896 Phase 2, Phase 3 Carboplatin plus Irinotecan vs Carboplatin plus Etoposide
15 A Prospective Randomized Study Comparing the Target Volume for Limited-stage Small Cell Lung Cancer Unknown status NCT01731548 Phase 2, Phase 3
16 Dalteparin in Preventing Blood Clots in Patients With Lung Cancer Unknown status NCT00519805 Phase 3 dalteparin
17 Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer Unknown status NCT00365105 Phase 3 zoledronic acid;Sm-153
18 A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer Completed NCT00717938 Phase 3 cisplatinum or carboplatin and e.g.etoposide.;cisplatinum or carboplatin and e.g.etoposide+enoxaparin
19 Bevacizumab in Extensive Small Cell Lung Cancer Completed NCT00930891 Phase 2, Phase 3 Standard Chemotherapy (PCDE or PE);Experimental Treatment (PCDE or PE + bevacizumab);Prerandomization Chemotherapy (PCDE or PE)
20 AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy Completed NCT00547651 Phase 3 Amrubicin;Topotecan
21 Early Versus Late Concurrent Chemoradiation for Limited Stage Small-cell Lung Cancer Completed NCT01125995 Phase 3
22 Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone Completed NCT01450761 Phase 3 Etoposide;Cisplatin;Carboplatin
23 A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa Completed NCT00119613 Phase 3 placebo;darbepoetin alfa
24 Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults Completed NCT00043927 Phase 3 topotecan/cisplatin;etoposide/cisplatin
25 Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer Completed NCT00143455 Phase 3 Etoposide + cisplatin;Irinotecan + cisplatin
26 Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer Completed NCT00363415 Phase 3 pemetrexed;etoposide;carboplatin
27 Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer Completed NCT00658580 Phase 3 Cisplatin + etoposide;Epirubicin + ifosfamide + etoposide
28 Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer Completed NCT00003011 Phase 3 marimastat;Placebo
29 Radiation Therapy Plus Combination Chemotherapy In Treating Patients With Limited Stage Small Cell Lung Cancer Completed NCT00003364 Phase 3 cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
30 Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer Completed NCT00003299 Phase 3 cisplatin;etoposide;paclitaxel
31 Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer Completed NCT00006352 Phase 3
32 Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer in Complete Remission Completed NCT00005062 Phase 3
33 Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer Completed NCT00061919 Phase 3 Carboplatin, etoposide & thalidomide;Carboplatin, etoposide & placebo
34 Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer Completed NCT00006349 Phase 3 donepezil hydrochloride
35 S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer Completed NCT00045162 Phase 3 cisplatin;etoposide;irinotecan hydrochloride
36 Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer Completed NCT00003279 Phase 3
37 Radiation Therapy to Prevent Brain Metastases in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer Completed NCT00016211 Phase 3
38 Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer Completed NCT00002822 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
39 Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer Completed NCT00003917 Phase 3 topotecan hydrochloride
40 A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC Completed NCT00144989 Phase 3 Etoposide and cisplatin after chemoradiotherapy;Irinotecan and cisplatin after chemoradiotherapy
41 Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer Completed NCT00320359 Phase 3 Intravenous topotecan/cisplatin;Intravenous etoposide/cisplatin
42 Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG Completed NCT00037713 Phase 3
43 A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer Completed NCT00349492 Phase 3 IP
44 Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer Completed NCT00041015 Phase 3 cisplatin;etoposide;topotecan hydrochloride
45 Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer Completed NCT00433498 Phase 3 carboplatin;cisplatin;etoposide phosphate;pravastatin sodium
46 Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer Completed NCT00660504 Phase 3 Amrubicin Hydrochloride;Etoposide-Cisplatin combined chemotherapy
47 Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide Completed NCT00290953 Phase 2, Phase 3 SR48692
48 Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer Completed NCT00276276 Phase 3 topotecan
49 National Lung Screening Trial (NLST) Screening Completed NCT00047385 Phase 3
50 Comparison of Nicotine Inhaler and/or Bupropion in Helping People to Stop Smoking and Prevent the Recurrence of Smoking Completed NCT00033592 Phase 3 bupropion hydrochloride;nicotine

Search NIH Clinical Center for Small Cell Carcinoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Small Cell Carcinoma

Anatomical Context for Small Cell Carcinoma

MalaCards organs/tissues related to Small Cell Carcinoma:

38
Lung, Brain, Prostate, Ovary, Cervix, Bone, Kidney

Publications for Small Cell Carcinoma

Articles related to Small Cell Carcinoma:

(show top 50) (show all 949)
# Title Authors Year
1
Evaluating Treatment Patterns for Small Cell Carcinoma of the Colon Using the National Cancer Database (NCDB). ( 29354876 )
2018
2
Advanced small cell carcinoma of the cervix - Successful treatment with concurrent etoposide and cisplatin chemotherapy and extended field radiation: A case report and discussion. ( 29255785 )
2018
3
Cytological features of small cell carcinoma of the ovary-hypercalcemic type/malignant ovarian rhabdoid tumor in ascitic fluid. ( 29446248 )
2018
4
Extrapulmonary small cell carcinoma: an unfortunate case of metastatic disease. ( 29309906 )
2018
5
Comments on "Treatment Strategies and Prognostic Factors of Limited-Stage Primary Small Cell Carcinoma of the Esophagus". ( 29425616 )
2018
6
Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. ( 29365144 )
2018
7
Orbital metastatic small cell carcinoma of the pancreas with optic nerve compression. ( 29426454 )
2018
8
Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase inhibition. ( 29440177 )
2018
9
Identification of Driver Mutations in Rare Cancers: The Role of SMARCA4 in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT). ( 29423809 )
2018
10
Combined small cell carcinoma with giant cell carcinoma component of the lung: A case successfully diagnosed by computed tomography-guided fine-needle aspiration cytology. ( 29399198 )
2018
11
The use of adaptive intensity-modulated radiotherapy in the treatment of small-cell carcinoma lung refractory to chemotherapy in a patient with preexisting interstitial lung disease. ( 29319036 )
2018
12
Response to "Comments on Treatment Strategies and Prognostic Factors of Limited-Stage Primary Small Cell Carcinoma of the Esophagus". ( 29425617 )
2018
13
An update on the developing mitotic inhibitors for the treatment of non-small cell carcinoma. ( 28836854 )
2017
14
Metachronous metastatic colonic small cell carcinoma and recurrent adenocarcinoma in a patient with ulcerative colitis. ( 29423143 )
2017
15
Dramatic Response of a Metastatic Primary Small-Cell Carcinoma of the Pancreas to a Trial of Immunotherapy with Nivolumab: A Case Report. ( 28878656 )
2017
16
Orthotopic neobladder in patient with locally advanced small cell carcinoma of the bladder: a case report and review of the literature. ( 28458816 )
2017
17
Adenocarcinoma of the Lung Acquiring Resistance to Afatinib by Transformation to Small Cell Carcinoma: A Case Report. ( 28878647 )
2017
18
Primary gastric small cell carcinoma. ( 28363459 )
2017
19
Therapeutic strategies and genetic profile comparisons in small cell carcinoma and large cell neuroendocrine carcinoma of the lung using next-generation sequencing. ( 29312580 )
2017
20
Composite hepatocellular carcinoma and small cell carcinoma with early nodal metastasis: A case report. ( 28834900 )
2017
21
Bilateral blindness with secondary retinitis pigmentosa following postoperative docetaxel and platinum combination chemotherapy in primary small-cell carcinoma of the endometrium: An unusual case report and review of the literature. ( 28413652 )
2017
22
Assessment of common somatic mutations of EGFR, KRAS, BRAF, NRAS in pulmonary non-small cell carcinoma using iPLEXAr HS, a new highly sensitive assay for the MassARRAYAr System. ( 28926605 )
2017
23
Small Cell Carcinoma Mimicking Acute Leukemia. ( 28794375 )
2017
24
The importance of recognizing paraneoplastic symptoms: a case report of Neuroendocrine Small Cell Carcinoma of the Endometrium presenting as Paraneoplastic Cushing's Syndrome. ( 29209490 )
2017
25
Metastasis of Esophageal Small Cell Carcinoma to the Appendix: A Case Report and Literature Review. ( 28886266 )
2017
26
A Long Survival Woman with Primary Small-Cell Carcinoma of the Gallbladder: Role of Chemotherapy Maintenance. ( 28744415 )
2017
27
The incidence of symptomatic brain metastases from extra-pulmonary small cell carcinoma: Is there a role for prophylactic cranial irradiation in a clinically relevant population cohort? ( 28662868 )
2017
28
Sarcomatoid carcinoma associated with small cell carcinoma of the urinary bladder: a series of 28 cases. ( 28827101 )
2017
29
Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma. ( 28753872 )
2017
30
Clinicopathologic and Immunohistochemical Study of Combined Small Cell Carcinoma and Urothelial Carcinoma Molecular Subtype. ( 29249035 )
2017
31
Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Clinical and Imaging Review. ( 28943050 )
2017
32
Primary small-cell carcinoma of the palate - the second case report worldwide. ( 29181083 )
2017
33
Clinicopathologic characteristics, therapy and outcomes of patients with primary ureteral small cell carcinoma: a case series and systematic review of the literature. ( 28860819 )
2017
34
Refractory Lactic Acidosis in Small Cell Carcinoma of the Lung. ( 28620552 )
2017
35
Association of Li-Fraumeni Syndrome With Small Cell Carcinoma of the Ovary, Hypercalcemic Type and Concurrent Pleomorphic Liposarcoma of the Cervix. ( 28177947 )
2017
36
A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity. ( 28723866 )
2017
37
Tumor-to-tumor metastasis: Small cell carcinoma lung metastasising into a follicular adenoma of the thyroid. ( 28195115 )
2017
38
Re: Advanced Small Cell Carcinoma of the Bladder: Clinical Characteristics, Treatment Patterns and Outcomes in 960 Patients and Comparison with Urothelial Carcinoma. ( 28505896 )
2017
39
Primary Upper Urinary Tract Small Cell Carcinoma: A Case Series and Literature Review. ( 29177194 )
2017
40
Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and EGFR-Mutated Lung Adenocarcinoma. ( 29169523 )
2017
41
Collision tumor of choriocarcinoma and small cell carcinoma of the stomach: A case report. ( 28709051 )
2017
42
Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type. ( 29102090 )
2017
43
Clinical analysis of small cell carcinoma of the bladder in Chinese: nine case reports and literature reviews. ( 28125986 )
2017
44
Primary Small Cell Carcinoma of the Hypopharynx: A Report of Two Cases and Review of Nine Additional Cases. ( 28804666 )
2017
45
SMARCA4 inactivating mutations cause concomitant Coffin-Siris syndrome, microphthalmia and small-cell carcinoma of the ovary hypercalcaemic type. ( 28608987 )
2017
46
High expression of Ki-67 is an independent favorable prognostic factor for esophageal small cell carcinoma. ( 28903420 )
2017
47
Treatment Patterns and Survival Outcomes for Patients with Small Cell Carcinoma of the Bladder. ( 28919521 )
2017
48
Molecular mechanisms of pathological tumor transformation and their clinical implications: predictors of pulmonary adenocarcinoma transformation into small cell carcinoma. ( 29268318 )
2017
49
Intensity-modulated radiation therapy for small cell carcinoma of the prostate: A case report. ( 28761390 )
2017
50
Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report. ( 28061471 )
2017

Variations for Small Cell Carcinoma

Expression for Small Cell Carcinoma

Search GEO for disease gene expression data for Small Cell Carcinoma.

Pathways for Small Cell Carcinoma

Pathways related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.58 EGFR KIT KLK3 PDGFRA PTEN TMPRSS2
2
Show member pathways
12.57 EGFR KIT PTEN SMARCA4 TP53
3
Show member pathways
12.53 EGFR KIT PDGFRA PTEN TP53
4 12.52 EGFR KIT KLK3 PDGFRA PTEN TP53
5 12.33 CALCA ENO2 NCAM1 NKX2-1 SYP
6 11.92 EGFR PTEN SMARCA4 TP53
7 11.79 EGFR PTEN SMARCA4 TP53
8 11.72 KIT NCAM1 PTPRC
9 11.68 EGFR KLK3 PTEN
10 11.62 KIT NCAM1 PTPRC
11 11.6 EGFR PDGFRA PTEN TP53
12 11.57 KIT NCAM1 PTPRC
13 11.38 KIT NCAM1 PDGFRA
14 11.34 EGFR PDGFRA TP53
15 11.25 ASCL1 NCAM1 PDGFRA SMARCA4 SYP
16 10.83 EGFR KIT PDGFRA PTEN TP53

GO Terms for Small Cell Carcinoma

Biological processes related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 9.88 ASCL1 EGFR KIT NKX2-1 SMARCA4
2 negative regulation of transcription, DNA-templated GO:0045892 9.85 ASCL1 CALCA NKX2-1 SMARCA4 TP53
3 MAPK cascade GO:0000165 9.8 EGFR KIT NCAM1 PDGFRA
4 wound healing GO:0042060 9.7 EGFR PDGFRA TP53
5 mast cell degranulation GO:0043303 9.54 CHGA KIT
6 positive regulation of cAMP metabolic process GO:0030816 9.51 CALCA CHGA
7 cerebral cortex cell migration GO:0021795 9.43 EGFR NKX2-1
8 tongue development GO:0043586 9.4 EGFR KIT
9 forebrain neuron differentiation GO:0021879 9.37 ASCL1 NKX2-1
10 positive regulation of phospholipase C activity GO:0010863 9.32 KIT PDGFRA
11 mast cell chemotaxis GO:0002551 9.26 CHGA KIT
12 cerebral cortex GABAergic interneuron differentiation GO:0021892 9.16 ASCL1 NKX2-1
13 cellular response to reactive oxygen species GO:0034614 9.13 EGFR PDGFRA TP53
14 mast cell cytokine production GO:0032762 8.62 CHGA KIT

Molecular functions related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.33 EGFR KIT PDGFRA
2 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.26 EGFR KIT
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 EGFR KIT PDGFRA
4 Ras guanyl-nucleotide exchange factor activity GO:0005088 8.92 EGFR KIT NCAM1 PDGFRA

Sources for Small Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....